{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-003807","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2023-06-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.905380+00:00","generated_at":"2026-06-14T05:43:33.578274+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Arbutus to present AB-729 and AB-836 data at EASL Congress 2023","bullets":["AB-729 + IFN in virally suppressed chronic HBV: well tolerated, mean HBsAg decline >1.6 log10 after 24 weeks.","88% of subjects achieved HBsAg <100 IU/mL; 2 subjects reached HBsAg <LLOQ during IFN treatment.","AB-836 capsid inhibitor: no viral breakthrough or enrichment of resistant variants after 28 days across 48 subjects.","Multiple core protein variants observed at higher frequencies, suggesting viral plasticity at those sites."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-003807","json":"https://secwatch.observer/filing/0001171843-23-003807.json","markdown":"https://secwatch.observer/filing/0001171843-23-003807.md","text":"https://secwatch.observer/filing/0001171843-23-003807.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323003807/0001171843-23-003807-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323003807/f8k_060523.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T05:43:33.578274+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}